Richard Wells, MD
Pulmonary Disease · Jackson, MSNPI 1285865162
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.4% of the total across 321 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 32 manufacturers reported payments, led by Actelion Pharmaceuticals US, Inc. at 26.4% of the total. Reporting peaked in 2022 at $1,778 and has fallen 73.6% since, to $470 in 2025.
Across 321 payments — averaging $21.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$2K
- Boehringer Ingelheim$722
- GSK$692
- AstraZeneca$512
- Pfizer$499
- United Therapeutics Corporation$442
- plus $2K from 26 others
Across 3 payments — averaging $3878.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Actelion Pharmaceuticals US, Inc.$12K
What the payments were for
- Food & beverage$6,77597%
- Education$1833%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 65 | $1,835 |
| Boehringer Ingelheim | 36 | $722 |
| GSK | 40 | $692 |
| AstraZeneca | 22 | $512 |
| Pfizer | 30 | $499 |
| United Therapeutics Corporation | 19 | $442 |
| Bayer | 14 | $335 |
| Regeneron Healthcare Solutions, Inc. | 12 | $305 |
| AbbVie | 14 | $249 |
| Mallinckrodt Hospital Products Inc. | 10 | $243 |
| Sanofi | 8 | $186 |
| Merck | 7 | $142 |
| Inari Medical, Inc. | 4 | $93 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $73 |
| Pulmonx Corporation | 4 | $72 |
| Johnson & Johnson | 4 | $71 |
| Insmed, Inc. | 4 | $59 |
| Astellas Pharma US Inc | 3 | $58 |
| Genentech USA, Inc. | 4 | $57 |
| Vapotherm Inc | 3 | $48 |
| Gilead | 3 | $45 |
| Ambu Inc. | 1 | $33 |
| Novartis | 2 | $29 |
| Mauna Kea Technologies, Inc. | 1 | $27 |
| Mallinckrodt Enterprises LLC | 1 | $21 |
| Philips North America LLC | 1 | $21 |
| ANI Pharmaceuticals, Inc. | 1 | $18 |
| Portola Pharmaceuticals, LLC | 1 | $18 |
| Mylan Specialty L.p. | 1 | $15 |
| Avanos Medical | 1 | $14 |
| La Jolla Pharmaceutical Company | 1 | $13 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,958 in reported general payments places this provider in the 55th percentile of 101 pulmonary disease providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 87 | $1,078,154 |
| UptraviSelexipag | 33 | $776,720 |
| AdempasRiociguat | 11 | $153,266 |
| Ambrisentan | 28 | $126,226 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $20,068 |
| Tadalafil | 33 | $18,373 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 35 | $16,353 |
| Bosentan | 12 | $14,934 |
| Incruse ElliptaUmeclidinium Bromide | 40 | $14,040 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 32 | $12,866 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 21 | $12,279 |
| EliquisApixaban | 17 | $11,882 |
| Spiriva HandihalerTiotropium Bromide | 15 | $7,292 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $5,923 |
| SymbicortBudesonide/Formoterol Fumarate | 21 | $4,931 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi, Bosentan | $1,835 | $1,869,808132 claims |
| BayerAdempas | $335 | $153,26611 claims |
| GSKTrelegy Ellipta, Incruse Ellipta, Anoro Ellipta, Breo Ellipta | $692 | $52,897119 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $512 | $17,21042 claims |
| Boehringer IngelheimStiolto Respimat | $722 | $16,35335 claims |
| PfizerEliquis | $499 | $11,88217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 101 pulmonary disease providers in Mississippi.
Other pulmonary disease in Jackson
- Demondes HaynesJackson$809K
- Michal SenitkoJackson$185K
- Andrew WilhelmJackson$51K
- Raymond PortisJackson$39K
- George AbrahamJackson$23K
- Maria RappaiJackson$20K
- Arash SamarghandiJackson$19K
- Kimberly DobbsJackson$14K
- Rajesh PatelJackson$13K
- Charles EvansJackson$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.